Skip to main content
HUTCHMED wins China approval for SYVIK in two blood disorders
Image for illustrative purposes only. Not a real photo.

HUTCHMED wins China approval for SYVIK in two blood disorders

By

Key points

  • HUTCHMED (NASDAQ:HCM) received China regulatory approval for SYVIK (sovleplenib) to treat two autoimmune blood disorders in adults.
  • Phase III trials showed durable platelet response rates of 48.4% and 66%, compared with 0% and 15% for placebo, respectively.
  • The approval makes SYVIK HUTCHMED's first internally developed immunology drug cleared for commercialization, with the company retaining worldwide rights.

HUTCHMED (NASDAQ:HCM) announced that China's National Medical Products Administration (NMPA) approved SYVIK (sovleplenib) for adults with chronic primary immune thrombocytopenia and warm antibody autoimmune hemolytic anemia, marking the company's first internally developed immunology drug approved for commercialization.

The approvals cover adults with chronic primary immune thrombocytopenia who have not responded adequately to at least one previous treatment and adults with warm antibody autoimmune hemolytic anemia who have had an insufficient response to corticosteroid therapy.

In the Phase III ESLIM-01 trial, SYVIK achieved a durable platelet response rate of 48.4%, compared with 0% among patients receiving placebo.

In the Phase III ESLIM-02 trial, the durable hemoglobin response rate during weeks 5–24 reached 66% with SYVIK, compared with 15% for placebo.

The US Food and Drug Administration granted orphan drug designations to sovleplenib for primary immune thrombocytopenia in October 2026 and autoimmune hemolytic anemia in November 2026, while HUTCHMED retains full worldwide development and commercialization rights.

Sovleplenib is an orally administered, selective spleen tyrosine kinase (Syk) inhibitor, and its approval adds an internally developed immunology treatment to HUTCHMED's portfolio of targeted therapies and immunotherapies.


Frequently asked questions